Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Minimum environmental impact ultra-efficient cores for aircraft propulsion. (MINIMAL)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Climate, Energy and Mobility
Theme: Mobility
Destination: Clean and competitive solutions for all transport modes
Action type: Research and Innovation actions
Countries involved: Sweden,Germany,Greece,Netherlands,United Kingdom
Call: Greenhouse gas aviation emissions reduction technologies towards climate neutrality by 2050 (HORIZON-CL5-2021-D5-01, 2021)
Start date: 2022-09-01
End date: 2026-08-31
Duration (months): 48.0
Total project cost (EUR): 3527276.0
EU funding (EUR): 3527276.0
Participants: 10
Project status: SIGNED

Building a sustainable and climate neutral future for aviation is an inevitable requirement for a society with increasing mobility needs. If we are to stabilise the global temperature below the 1.5°C threshold set by the Paris Agreement, rapid action is to be taken. MINIMAL will contribute to a radical transformation in air transport by providing disruptive ultra-efficient and low-emission technologies that will, in combination with the aviation ecosystem, sustainably reduce the climate impact of aviation. The MINIMAL project will, through an unprecedented effort between European engine OEMs, world leading atmospheric physics scientists, and lead researchers in combustion and propulsion, attack the major sources of non-CO2 and CO2 emissions in aeroengines. This will be accomplished with the introduction of climate optimised new propulsion systems based on composite cycle engine technology, that provides unparalleled flexibility with respect to operations, and that has the potential to eliminate the large sources of effective radiative forcing by 2035: 80% reduction from contrails, 52% reduction from net-NOx, and 36% fuel burn reduction resulting in 36% to 100% CO2 reduction, depending on the fuel used. Results will allow assessing the interdependencies between non-CO2 and CO2 effects already during the early stages of aero-thermal-mechanical design and converge into engine options that have minimum climate impact. The findings are supported by numerical (TRL 2) and experimental (TRL 3) proof of concept of Low-NOx opposed-piston constant volume combustion technology with pre-micromixing of hydrogen. In MINIMAL we understand the urgency and aim for maximum impact. Aggressive, but realistic roadmaps will be outlined together with regular exchanges in major industry research centres to develop these technologies into products and bring them to in 2035-2040.

Keywords: innovation cycles pressure rise combustion heat management cryogenic hydrogen contrail cirrus mitigation gas turbine technology nox mitigation climate optimised cores
Biodiversity Digital Twin for Advanced Modelling, Simulation and Prediction Capabilities (BioDT)

Framework: Horizon Europe — Excellent Science
Programme: Research infrastructures
Theme: Research infrastructures
Destination: Technology and infrastructures
Action type: Research and Innovation actions
Countries involved: Finland,Italy,Austria,Denmark,Norway,Netherlands,Germany,Spain,United Kingdom,Czechia,Estonia,Sweden
Call: Interdisciplinary digital twins for modelling and simulating complex phenomena at the service of research infrastructure communities (HORIZON-INFRA-2021-TECH-01, 2021)
Start date: 2022-06-01
End date: 2025-05-31
Duration (months): 36.0
Total project cost (EUR): 11059061.0
EU funding (EUR): 11059061.0
Participants: 22
Project status: SIGNED

With our planet facing an increasing reduction in biodiversity, it is of the utmost importance to understand the way climate, humans, pollution and other factors affect biodiversity. This need is urgent since biodiversity loss directly impacts our ability as humans to live. For example, this loss reduces the efficiency with which ecological communities capture essential resources, produce biomass, decompose organic matter and recycle nutrients. Furthermore, there is increasing evidence that a lack of contact with natural biodiversity impacts human health through negative effects in the microbiome and immune system. microbiome and immune system. Understanding the forces shaping biodiversity is the basis for any rational management of natural resources and will be a key enabler of the EU Biodiversity Strategy 2030 which aims to put biodiversity in Europe on the path to recovery by 2030 for the benefit of people, climate and the planet. In particular, we need to be able to better predict global biodiversity dynamics: how species interact with their environment and with each other. Our goal is to push the current boundaries of predictive understanding of biodiversity dynamics by developing a Digital Twin providing advanced modelling, simulation and prediction capabilities. By exploiting in new ways existing technologies and data available across relevant research infrastructures, the BioDT project will be able to more accurately model interaction between species and their environment. Scientists at Research Infrastructures will be able to use the BioDT to 1) better observe changes in biodiversity, 2) relate these changes to possible causes, and 3) better predict effects of changes based on influences on these causes by either climate or human intervention. Our consortium brings together a dynamic team of experts in biodiversity, high performance computing, artificial intelligence and FAIR data to realise the first biodiversity Digital Twin prototype.

Keywords: biodiversity,digital twin,modelling,simulation,prediction,high performance computing,artificial intelligence
Improving cellular cancer immunotherapy using chemotactic metabolite receptors (MetaboTract)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Germany
Call: MSCA Postdoctoral Fellowships 2022 (HORIZON-MSCA-2022-PF-01, 2022)
Start date: 2024-09-01
End date: 2026-08-31
Duration (months): 24.0
Total project cost (EUR): 189687.36
EU funding (EUR): 189687.36
Participants: 1
Project status: SIGNED

Chimeric antigen receptor T cell (CAR T) cellular immunotherapy has revolutionized treatment for patients with hematological cancers, but largely failed to provide benefits for patients with solid tumors. Ineffective CAR T migration into solid tumors caused by the lack of recruitment signals, including chemokines, is a key gap for current cellular immunotherapies. The very common accumulation of metabolites in tumors provides a yet unrecognized opportunity to guide immune cells into tumors. Therefore, my overall research objective for this project is to generate and use novel chemotactic metabolite receptors (MetaboTract) to enhance the efficacy of CAR T and natural killer (NK) in solid tumors. This innovative approach is expected to impact the therapeutic options for cancer patients with poorly infiltrated tumors and enhance the EU’s competitiveness in the rapidly expanding market of cellular immunotherapies. Applying the gained knowledge on CAR NK cells could additionally reduce treatment costs and accelerate deployment of cellular therapies to patients. During the MSCA fellowship, I will learn vital new skills including cell migration assays, in vivo models for immunotherapies, project management, exploitation, and leadership in the renowned laboratory of Prof. Sebastian Kobold at the Ludwig-Maximilians-University (LMU) in Munich. The expertise of Prof. Kobold’s lab with chemokine receptor CAR T cells and in vivo models together with my complementary skills in cellular immunology, NK cells, imaging, and bioinformatics gives the project a high likelihood of success. The publication of the results, the gained knowledge and skills, and the demonstrated mobility will strengthen my scientific independence and help me achieve my career goal of becoming a research group leader in cellular cancer immunotherapy.
Cultivating hope one star sperm at a time (Spermotile)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Transition
Destination: Open to supporting projects in all areas of science, technology,...
Action type: EIC actions
Countries involved: Norway
Call: Transition Open 2024 (HORIZON-EIC-2024-TRANSITION-01, 2024)
Start date: 2025-04-01
End date: 2027-09-30
Duration (months): 30.0
Total project cost (EUR): 2499906.25
EU funding (EUR): 2499906.25
Participants: 1
Project status: SIGNED

The Spermotile project addresses the growing issue of male infertility, which affects approximately 1 in 6 couples globally. Male infertility is responsible for 40% of fertility challenges and has been increasingly prevalent due to various environmental, genetic, and lifestyle factors. Assisted Reproduction Technologies (ARTs) such as Intrauterine Insemination (IUI), In Vitro Fertilization (IVF), and Intracytoplasmic Sperm Injection (ICSI) rely on high-quality sperm selection to maximize fertility success. However, current sperm selection techniques are manual, low-throughput, and often subjective, leading to inefficiencies and increased costs. Spermotile offers a breakthrough solution for ART through an automated, AI-driven platform that integrates three key technologies: stain-free optical microscopy, a Computer-Assisted Semen Analysis (CASA) engine powered by trustworthy AI, and a novel ActiveFilter microfluidic chip. The system selects and collects the highest quality "star sperm" for use in ART procedures. This selection process is performed with high throughput, minimal manual input, and without damaging sperm quality, significantly improving the efficiency and outcomes of fertility treatments. Spermotile integrates easily into clinical workflows, adding just 30 minutes and minimal technician time. It improves ART success rates by up to 12%, reduces the number of cycles needed, boosts clinic throughput fivefold, and lowers costs for both patients and clinics. Spermotile builds on prior European projects, including MUSICAL, 3D-nanoMorph, and ERC PoC-funded Spermotile. Aiming for TRL 6 and EU regulatory approval by 2027, it holds three pending patents and a growing IP portfolio, positioning it for commercialization. By addressing SDGs 3.7 and 5.6, it also minimizes environmental impact through energy-efficient AI and ethical data management. The goal is to establish Spermotile as a standard tool in fertility clinics, revolutionizing male infertility treatment.

Keywords: male fertility,assisted reproduction,ivf,icsi
Nanomedicine Approach to Normalize Erythrocyte Maturation in Congenital Anemia by messenger RNA (NANEMIAR)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Health
Theme: Health
Destination: Tackling diseases and reducing disease burden
Action type: Research and Innovation actions
Countries involved: Spain,Netherlands,France
Call: Development of new effective therapies for rare diseases (HORIZON-HLTH-2022-DISEASE-06-two-stage, 2022)
Start date: 2023-10-01
End date: 2026-09-30
Duration (months): 36.0
Total project cost (EUR): 2682897.5
EU funding (EUR): 2682897.5
Participants: 4
Project status: SIGNED

Messenger RNA (mRNA) has recently proven itself as a prophylactic modality that can be rapidly developed and employed with high efficacy and low toxicity. Compared to DNA-based gene therapy, mRNA has significant advantages including higher intrinsic safety (non-integrating), lower cost of development, and less stringent regulatory requirements for clinical approval. In the NANEMIAR project, we take advantage of these benefits to kill 2 birds with 1 stone: first, we develop a first-of-its-kind nanomedicine for congenital anemia, a group of rare, inherited blood disorders characterized by ineffective red blood cell production. Our proposed bone marrow-targeted mRNA-based therapy contributes to the first Horizon Europe strategic plan (2021-2024) for new and advanced therapies for non-communicable diseases and is expected to be a vast improvement over current treatment options in terms of efficacy and safety. Second, we provide critical knowledge on targeted non-viral polynucleotide delivery, with a platform that can be exploited for next-generation cell and gene therapy in a broader context. To achieve this, our consortium combines the unique cell-targeting and mRNA knowledge from the Dutch Biotech Mercurna with two excellent research partners (from Spain and France) who have demonstrated expertise in the field of anemia. By focusing on the well-recognized rare disease model, beta-thalassemia, and combining an established mouse model, patient material, and previous drug development experience we build a convincing case to treat congenital anemia.

Keywords: mrna,erythropoiesis,lipid nanoparticles,targeting,health,congenital anemia
Prediction, Monitoring and Personalized Recommendations for Prevention and Relief of Dementia and Frailty (COMFORTAGE)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Health
Theme: Health
Destination: Staying Healthy in a rapidly changing society
Action type: Research and Innovation actions
Countries involved: Greece,Norway,Cyprus,Netherlands,Germany,Italy,Spain,Romania,Slovenia,Belgium,Poland,United Kingdom
Call: The Silver Deal - Person-centred health and care in European regions (HORIZON-HLTH-2023-STAYHLTH-01, 2023)
Start date: 2024-01-01
End date: 2027-12-31
Duration (months): 48.0
Total project cost (EUR): 17591490.0
EU funding (EUR): 17591490.0
Participants: 41
Project status: SIGNED

COMFORTAGE is a joint effort of medical experts (i.e., neurologists, psychiatrists, neuropsychologists, nurses, memory clinics), social scientists and humanists, technical experts (i.e., data scientists, AI experts, robotic experts) and Digital Innovation Hubs to establish a pan European framework for Community-based, Integrated and People-Centric prevention, monitoring and progression managing solutions for age-related diseases and disabilities. The project’s framework will be empowered by a unique combination and integration of: (i) Medical/clinical innovations (e.g., novel approaches to risk factor analysis and personalized prediction, AI-based medical devices, integrated data sources of age-related clinical evidence, and evidence-based Healthcare Technology Assessment (HTA)), (ii) Cutting edge AI innovations (e.g., explainable AI (XAI), secure AI, serious games, Patient Digital Twins, Virtual Assistive technologies) for trusted, accurate, secure and personalized clinical decision making, (iii) Digital Innovation Hubs (e.g. Smart Homes, robotics and Living Labs) to facilitate and promote research activities in the health and wellbeing domain, and (iv) social innovations for promoting innovative views and co-creating new or improved solutions for assistance and improvement of social integration and interaction. COMFORTAGE will facilitate the integration, harmonization, and management of a host of different data sources, including biobanks, cohorts, medical records, longitudinal observational studies, real-world data about patients, as well of alternative secondary data sources, such as sensors, wearables and mobiles in a standardized structure called Holistic Health Records (HHRs). COMFORTAGE will become a catalyst to help prevent, monitor, and manage progression of age-related diseases and disabilities, especially of dementia and frailty, based on high-end research and analysis of the utilization of the aforementioned technologies.

Keywords: ageing,frailty,health literacy,primary prevention,personalised prevention,personalised treatment,wellbeing
Implementation research on the tailored, multidisciplinary NCD prevention package FRESHAIR4LIFE: Targeting tobacco and air pollution exposure in mid- to late adolescents in disadvantaged populations (FRESHAIR4LIFE)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Health
Theme: Health
Destination: Tackling diseases and reducing disease burden
Action type: Research and Innovation actions
Countries involved: Netherlands,United Kingdom,Kyrgyzstan,Greece,Romania,Belgium,Pakistan,Uganda
Call: Non-communicable diseases risk reduction in adolescence and youth (Global Alliance for Chronic Diseases - GACD) (HORIZON-HLTH-2022-DISEASE-07, 2022)
Start date: 2023-01-01
End date: 2026-12-31
Duration (months): 48.0
Total project cost (EUR): 2149813.75
EU funding (EUR): 2149813.75
Participants: 14
Project status: SIGNED

Non-Communicable Diseases (NCD) are the leading cause of ill health and premature mortality. Although we know how to mitigate risk factors and prevent NCDs, we have failed to apply this knowledge, especially in disadvantaged populations. FA4LIFE aims to bridge this translational gap, and gain knowledge, resources and capacity to optimize implementation of multi-level, evidence-based tobacco and air pollution (AP) exposure prevention packages targeting adolescents in disadvantaged populations. To do so, FA4LIFE will work in five countries; Greece, the Kyrgyz Republic, Pakistan, Romania and Uganda. All face a high NCD burden, but their contexts differ significantly. These differences provide opportunity to gain implementation knowledge and resources that can be extrapolated to settings worldwide. All FA4LIFE activities are supported by dual capacity building: creating youth advocacy and professional leadership. In each setting, we will: 1. Perform situational analysis (incl. affordability) and establish sustainable stakeholder engagement teams 2. Use the Prevention palette method' to co-create a tailored, evidence-based FA4LIFE prevention package targeting tobacco and AP exposure in mid- to late adolescents, mindful of equity 3. Implement, evaluate and iteratively refine the FA4LIFE prevention package 4. Optimize sustainable implementation and equitable impact by building dual capacity, via youth advocacy digital initiatives, community leadership schools and Teach-the-Teacher programs. A robust and innovative dissemination, exploitation and communication plan, including the FA4LIFE Case For Action, the FA4LIFE implementation toolbox, and broad youth advocacy-informed social media strategy will promote upscaling and maximize global impact on NCD burden, especially in those adolescents most at risk or in need in disadvantaged populations.

Keywords: implementation research ncd prevention adolescents tobacco air pollution disadvantaged populations youth advocacy
Renewable Hydrogen for Inland Waterway Emission Reduction (RH2IWER)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Climate, Energy and Mobility
Theme: Public-private partnerships
Destination: Clean Hydrogen
Action type: Innovation actions
Partnership: CLEANH2 (JU-JTI)
Countries involved: Finland,Denmark,France,Italy,Netherlands,Belgium,Germany
Call: Large scale demonstration of hydrogen fuel cell propelled inland waterway vessels (HORIZON-JTI-CLEANH2-2022-1, 2022)
Start date: 2023-03-01
End date: 2027-08-31
Duration (months): 54.0
Total project cost (EUR): 20531971.5
EU funding (EUR): 14998541.38
Participants: 16
Project status: SIGNED

The main aim of RH2IWER is to create a solid basis for the acceleration of hydrogen fuel cell powered vessels in inland waterway shipping by demonstrating six commercially operated vessels. These vessels are of varying lengths and types – 86m, 110m and 135m; container, bulk and tanker vessels with installed power ranging from 0.6 to ~2 MW. The project will also work with standardization of containerized fuel cell and hydrogen solutions. With the demonstration, standardization work and multi-level analysis, combined with vigorous dissemination and communication measures, RH2IWER project will create a basis on which the shipping industry can significantly reduce their environmental footprint and remove emissions from their entire fleet in the future. The inland waterway fleet comprises a total of more than 15,000 vessels and the vessels within RH2IWER are representative of the typical dry and liquid cargo vessels in the Rhine and Danube fleets, amounting to 12,800 vessels or roughly 80% of the inland waterway fleet. The lessons learned from developing fuel cell and hydrogen solutions for the vessels in this project could be applied more or less directly to these vessels, which would then immediately reduce the GHG emissions from these ships to zero. The consortium includes 14 European partners, with five shipowners Future Proof Shipping, Theo Pouw, VT Shipping, DFDS and Compagnie Fluviale de Transport with its affiliated entity Sogestion. The shipowners are supported by two of the main maritime fuel cell manufacturers Ballard Europe and Nedstackl, as well as world leading gas company Air Liquide and its affiliated entities Air Liquide Belge and L'Air Liquide SA. Lastly, highly respected knowledge institutions VTT, Stichting Projecten Binnenvaart and University of Genova with their affiliated entity H2Boat, will assist the companies in successful deployment as well as the dissemination, replication and exploitation of these demonstrations and technologies.

Keywords: fuel cells hydrogen inland waterways container vessel bulk carrier tanker
Tracking the deep evolutionary origins of neurons (ORIGINEURO)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Consolidator grants
Action type: ERC actions
Panel: Environmental B iology, Ecology  and E volution
Panel description: For all organisms : Ecology, biodiversity, environmental change , evolutionary biology, behavioural ecology, microbial ecology , marine biology, ecophysiology, theoretical developments and mod elling
Countries involved: Norway
Call: ERC CONSOLIDATOR GRANTS (ERC-2021-COG, 2021)
Start date: 2023-01-01
End date: 2027-12-31
Duration (months): 60.0
Total project cost (EUR): 2000000.0
EU funding (EUR): 2000000.0
Participants: 1
Project status: SIGNED

The evolutionary origin of first neurons was key for animals as it allowed them to rapidly detect environmental cues and to coordinate responses to threats or opportunities. The evolutionary origin of neurons however remains a highly debated and largely enigmatic subject since there is no broad agreement on the relationships at the base of the animal tree and not all non-bilaterian animals have neurons. Strikingly, early branching animals, as well as their closest unicellular relatives already contain many components of the molecular toolkits for neuronal functions. ORIGINEURO addresses fundamental questions regarding the evolutionary origin of synapses and neurons from molecular to cellular scales. My recent studies on choanoflagellates, the closest living relatives of all animals, and ctenophores (comb jellies), strong candidates for one of the first animal lineages, are providing exciting, new and surprising clues into the ancestry of synaptic proteins including the discovery of a neurosecretory apparatus in choanoflagellates and a unique nervous system in ctenophores. The proposed 5-year programme brings together correlative volume electron microscopy, super-resolution imaging, quantitative live cell imaging, state-of-the-art molecular biology and single cell RNA sequencing focusing on a ctenophore as model organism. Objective 1 will provide a detailed understanding of the ultrastructure and connectivity of ctenophore neurons forming the subepithelial nerve net. Objective 2 will shed light on the so far elusive ctenophore neuron development. By functionally characterizing ctenophore neurons (Objective 3) I will understand how they work and what they do. ORIGINEURO fills a research gap and will provide insights into how many ways to build a neural network. Thus, ORIGINEURO aims at challenging the paradigm of network activity emerging through cellular diversification and synaptic connections.

Keywords: ctenophore,synapse,neuron,evolution,neuropeptides